This multicenter single-arm phase II study evaluated the addition of pazopanib to concurrent weekly paclitaxel following doxorubicin and cyclophosphamide as neoadjuvant therapy in human epidermal growth factor receptor (HER2)-negative locally advanced breast cancer (LABC). The combination does not appear to warrant further evaluation in the neoadjuvant setting for breast cancer.

READ FULL ARTICLE Curated publisher From Mdlinx